Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia
Open Access
- 18 May 2005
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 5 (1) , 10
Abstract
Background: There are no standard criteria for when to discontinue intravenous antimicrobial therapy (IVAMT) in children with febrile neutropenia (FN), but it is now common to discontinue IVAMT and discharge patients with an absolute neutrophil count (ANC) ≤ 500 /mm3. The purpose of this study was to evaluate the outcome of a large cohort of children with FN who had IVAMT discontinued with an ANC ≤ 500 /mm3 Methods: A retrospective chart review was completed of patients in the Northern Alberta Children's Cancer Program with FN and no apparent clinical source of fever from June 1, 1997 to July 1, 2002. Results: Out of a total of 275 patients, 127 (46%) had at least one episode of FN, with FN occurring in patients with sarcomas more commonly than in those with leukemia/ lymphoma and least in those with other solid tumors. In 59 of 276 episodes of FN (21%) patients had a microbiologically defined infection at admission. Of the 217 remaining episodes, 112 of 199 patients (56%) with known neutrophil counts had IVAMT discontinued before their absolute neutrophil count (ANC) reached 500 /mm3 at the discretion of the clinician. Fever recurred in only two of these patients after discharge, and there were no bacterial infections diagnosed after parenteral antibiotics were discontinued. Conclusion: Even without use of standard criteria for early discharge, clinicians appear to be skilled at selecting children with FN who can safely have IVAMT discontinued with an ANC ≤ 500 /mm3.Keywords
This publication has 12 references indexed in Scilit:
- Predicting bacteremia in children with fever and chemotherapy-induced neutropeniaThe Pediatric Infectious Disease Journal, 2004
- Prospective Evaluation of a Model of Prediction of Invasive Bacterial Infection Risk among Children with Cancer, Fever, and NeutropeniaClinical Infectious Diseases, 2002
- Evolving concepts of management of febrile neutropenia in children with cancerMedical and Pediatric Oncology, 2002
- Value of Electronic Data for Model Validation and Refinement: Bacteremia Risk in Children With Fever and NeutropeniaJournal of Pediatric Hematology/Oncology, 2002
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- Risk Factors in Children With Fever and NeutropeniaJournal of Clinical Oncology, 2001
- Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipientsThe Lancet, 2001
- Randomized Placebo-Controlled Trial of Oral Antibiotics in Pediatric Oncology Patients at Low-Risk With Fever and NeutropeniaJournal of Pediatric Hematology/Oncology, 2000
- “Low-Risk” Prediction Rule for Pediatric Oncology Patients Presenting With Fever and NeutropeniaJournal of Clinical Oncology, 2000
- Pneumonia in Febrile Neutropenic Patients and in Bone Marrow and Blood Stem-Cell Transplant Recipients: Use of High-Resolution Computed TomographyJournal of Clinical Oncology, 1999